Sinopharm says data ‘better than expected” for COVID-19 vaccines
HONG KONG/BEIJING: China National Pharmaceutical Group (Sinopharm) said on Wednesday The data from large-scale, late-stage clinical trials for its unit’s COVID-19 vaccine are “better than expected”. Sinopharm’s unit China National Biotec Group (CNBG) has moved two vaccine applicants into Phase 3 clinical trials outside China in multiple countries including the United Arab Emirates (UAE), Bahrain … Read more